Bonus BioGroup announced that first transplantation of its proprietary live bone grafts in human was performed successfully. The clinical trial is designed to treat deficient facial bone tissues, including upper and lower jawbone cavitations. The transplantation made of live bone implants comprising of cells originating from patients’ own fat tissue and manufactured in Bonus BioGroup’s labs.
The first patient enrolled for this clinical trial passed the first stages of the trial aimed at successful incorporation of the bone graft within the patient’s body. These stages consisted of harvesting a fat tissue sample from the patient, transportation of the sample to Bonus BioGroup’s manufacturing facility, extraction of cells from the sample tissue, cultivation of those cells required for the generation of the human bone graft, production of the live human bone graft, transportation of the graft back to the medical site and its transplantation into the patient.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
As the manufactured live human bone graft originates in the fat sample of the patient receiving the graft, the company expects the graft to be fully tolerated, and to not induce any immunological rejection. Upon exposure to the newly-transplanted graft, the patient’s immune system is expected to recognize the biological similarity between the patients’ body and the graft manufactured from the patient’s own cells by Bonus BioGroup. For this reason it is anticipated that graft rejection – a frequent phenomenon in foreign donor tissue transplantation – shall be avoided.
The manufacturing process of Bonus BioGroup’s viable human bone graft started with the collection of a fat tissue sample from the first patient, in the medical site. The fat tissue sample was transported within several hours to Bonus BioGroup’s manufacturing facility where cells required for the bone graft production were extracted from the sample tissue and the generation of a transplantable and personalized live human bone graft began. As transplantation time approached, the ready-to-use graft was transported to the medical site, and transplantation followed shortly.
Shai Meretzki, CEO of Bonus BioGroup: “Years of stem cell research and development by Bonus BioGroup are now culminating in the first autologous transplantation of a human bone manufactured outside of the patient’s body. This successful transplantation points to the company’s aptitude to produce viable human implants in our manufacturing facility and to transplant them back into the patients. We very much look forward now to the next four months, during which we shall follow the healing process of the deficient bone until it is fully repaired.”